Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid.

Lifke V, Kollmorgen G, Manuilova E, Oelschlaegel T, Hillringhaus L, Widmann M, von Arnim CAF, Otto M, Christenson RH, Powers JL, Shaw LM, Hansson O, Doecke JD, Li QX, Teunissen C, Tumani H, Blennow K.

Clin Biochem. 2019 May 23. pii: S0009-9120(19)30492-8. doi: 10.1016/j.clinbiochem.2019.05.005. [Epub ahead of print]

2.

Acquired Resistance to Antibody-Drug Conjugates.

Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G.

Cancers (Basel). 2019 Mar 20;11(3). pii: E394. doi: 10.3390/cancers11030394. Review.

3.

The Role of micro RNAs in Breast Cancer Metastasis: Preclinical Validation and Potential Therapeutic Targets.

Weidle UH, Dickopf S, Hintermair C, Kollmorgen G, Birzele F, Brinkmann U.

Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):17-39. Review.

4.

A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer.

Kollmorgen G, Palme K, Seidl A, Scheiblich S, Birzele F, Wilson S, Clemens C, Voss E, Kaufmann M, Hirzel K, Rieder N, Krippendorff BF, Herting F, Niederfellner G.

Sci Rep. 2017 Dec 22;7(1):18086. doi: 10.1038/s41598-017-17329-7.

5.

Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Weidle UH, Birzele F, Kollmorgen G, Rueger R.

Cancer Genomics Proteomics. 2016 11-12;13(6):407-423. Review.

6.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

7.

Dissection of the Process of Brain Metastasis Reveals Targets and Mechanisms for Molecular-based Intervention.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2016 Jul-Aug;13(4):245-58. Review.

PMID:
27365375
8.

Molecular Basis of Lung Tropism of Metastasis.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2016 Mar-Apr;13(2):129-39. Review.

PMID:
26912803
9.

Molecular Mechanisms of Bone Metastasis.

Weidle UH, Birzele F, Kollmorgen G, Rüger R.

Cancer Genomics Proteomics. 2016 Jan-Feb;13(1):1-12. Review.

PMID:
26708594
10.

Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy.

Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Harring SV, Bauss F, Burtscher H, Lammers R, Bossenmaier B.

Mol Oncol. 2013 Dec;7(6):1142-51. doi: 10.1016/j.molonc.2013.08.009. Epub 2013 Sep 3.

11.

Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation.

Kollmorgen G, Bossenmaier B, Niederfellner G, Häring HU, Lammers R.

PLoS One. 2012;7(12):e53050. doi: 10.1371/journal.pone.0053050. Epub 2012 Dec 31.

12.

Sharpin contributes to TNFα dependent NFκB activation and anti-apoptotic signalling in hepatocytes.

Sieber S, Lange N, Kollmorgen G, Erhardt A, Quaas A, Gontarewicz A, Sass G, Tiegs G, Kreienkamp HJ.

PLoS One. 2012;7(1):e29993. doi: 10.1371/journal.pone.0029993. Epub 2012 Jan 9.

Supplemental Content

Loading ...
Support Center